Swipe om te navigeren naar een ander artikel
This work was previously presented in part as Poster Number 213 at the American Academy of Neurology meeting April 22–28 2017 in Boston, MA, but it has not been published elsewhere.
Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18–60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo for 8 weeks, washed out for 4 weeks, then crossed over to the opposite treatment. There were no serious adverse events. Subjects were significantly lower on the Aberrant Behavioral Checklist for Irritability (ABC-IR) (F1,10 = 7.42; p = 0.021). Improvements in aggression and Clinical Global Impression were also seen. The findings suggest that DM/Q is well-tolerated and associated with improvements in irritability and aggression in adults with autism.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Aman, M., Rettiganti, M., Nagaraja, H. N., Hollway, J. A., McCracken, J., McDougle, C. J., et al. (2015). Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology, 25(6), 482–493. https://doi.org/10.1089/cap.2015.0005. CrossRefPubMedPubMedCentral
Baio, J., Wiggins, L., Christensen, D. L., Maenner, M. J., Daniels, J., Warren, Z., et al. (2018). Prevalence of autism spectrum disorder among children aged 8 years—Autism and developmental disabilities monitoring network, 11 sites, United States, 2014. MMWR Surveillance Summaries, 67(6), 1–23. https://doi.org/10.15585/mmwr.ss6706a1. CrossRefPubMedCentral
Bauman, M. L., & Kemper, T. L. (1994). The neurobiology of autism. Baltimore: Johns Hopkins University Press.
Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22(5), 574–579. CrossRefPubMed
Hammond, F. M., Alexander, D. N., Cutler, A. J., D’Amico, S., Doody, R. S., Sauve, W., et al. (2016). PRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurology, 16, 89. https://doi.org/10.1186/s12883-016-0609-0. CrossRefPubMedPubMedCentral
IBM SPSS Statistics for Windows, (2012). vol 21.0. Armonk: IBM Corp.
King, B. H., Wright, D. M., Handen, B. L., Sikich, L., Zimmerman, A. W., McMahon, W., et al. (2001). Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40(6), 658–665. CrossRefPubMed
Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119. https://doi.org/10.1097/CHI.0b013e3181b76658. CrossRefPubMed
Margari, L., Matera, E., Craig, F., Petruzzelli, M. G., Palmieri, V. O., Pastore, A., et al. (2013). Tolerability and safety profile of risperidone in a sample of children and adolescents. International Clinical Psychopharmacology, 28(4), 177–183. https://doi.org/10.1097/YIC.0b013e328362497b. PubMed
Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., et al. (2016). An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety, 15(10), 1329–1347. https://doi.org/10.1080/14740338.2016.1201475. CrossRefPubMed
Pattee, G. L., Wymer, J. P., Lomen-Hoerth, C., Appel, S. H., Formella, A. E., & Pope, L. E. (2014). An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Current Medical Research and Opinion, 30(11), 2255–2265. https://doi.org/10.1185/03007995.2014.940040. CrossRefPubMedPubMedCentral
Zimmerman, A. (1991). Treating autism and other developmental disorders in children with NMDA receptor antagonists. Patent 4,994,467. https://patentimages.storage.googleapis.com/b7/68/af/6bd5da44812183/US4994467.pdf.
- A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism
- Springer US
Journal of Autism and Developmental Disorders
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432